Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong; Qun Wang; Weimin Mao; Lin Xu; Lin Wu; Yi Shen; Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Fei Ke; Xiaofei Li; Jian Li; Cheng Huang; Zhidong Liu; Shun Xu; Ke‐Neng Chen; Shidong Xu; Lunxu Liu; Ping Yu; Buhai Wang; Haitao Ma; Hong‐Hong Yan; Xue‐Ning Yang; Qing Zhou; Yi‐Long Wu; Yi‐Long Wu; Qun Wang; Weimin Mao; Lin Wu; Yi Shen; Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Fei Ke; Xiaofei Li; Jian Li; Cheng Zhi Huang; Zhidong Liu; Shun Xu; Ke‐Neng Chen; Shidong Xu; Lunxu Liu; Ping Yu; Buhai Wang; Haitao Ma; Siyu Wang; Jian Hu; Wei Liu; Wěi Li; Jianhua Shi

doi:10.1016/s1470-2045(17)30729-5

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong(Guangdong General Hospital), Qun Wang(The First Affiliated Hospital, Sun Yat-sen University), Weimin Mao(Zhejiang Cancer Hospital), Lin Xu(First Hospital of China Medical University), Lin Wu(Hunan Cancer Hospital), Yi Shen(Qingdao University), Yu Liu(Liaoning Cancer Hospital & Institute), Chun Chen(Fujian Medical University), Ying Cheng(Jilin Province Tumor Hospital), Lin Xu(Jiangsu Cancer Hospital), Jun Wang(Peking University People's Hospital), Fei Ke(Tongji University), Xiaofei Li(Tang Du Hospital), Jian Li(Peking University), Cheng Huang(Fujian Provincial Cancer Hospital), Zhidong Liu(Beijing Chest Hospital), Shun Xu(Harbin Medical University), Ke‐Neng Chen(Peking University), Shidong Xu(First Hospital of China Medical University), Lunxu Liu(West China Hospital of Sichuan University), Ping Yu(Sichuan Cancer Hospital), Buhai Wang(Northern Jiangsu People's Hospital), Haitao Ma(Soochow University), Hong‐Hong Yan(Guangdong General Hospital), Xue‐Ning Yang(Guangdong General Hospital), Qing Zhou(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong General Hospital), Qun Wang(Fudan University), Weimin Mao(Zhejiang Cancer Hospital), Lin Wu(Hunan Cancer Hospital), Yi Shen(Qingdao University), Yu Liu(Liaoning Cancer Hospital & Institute), Chun Chen(Union Hospital), Ying Cheng(Jilin Province Tumor Hospital), Lin Xu(Jiangsu Cancer Hospital), Jun Wang(Peking University), Fei Ke(Shanghai Pulmonary Hospital), Xiaofei Li(Tang Du Hospital), Jian Li(Peking University First Hospital), Cheng Zhi Huang(Fujian Provincial Cancer Hospital), Zhidong Liu(Beijing Chest Hospital), Shun Xu(Sun Yat-sen University), Ke‐Neng Chen(Peking University Cancer Hospital), Shidong Xu(Zhongshan Hospital), Lunxu Liu(West China Hospital of Sichuan University), Ping Yu(Sichuan Cancer Hospital), Buhai Wang(Northern Jiangsu People's Hospital), Haitao Ma(Soochow University), Siyu Wang(Northern Jiangsu People's Hospital), Jian Hu(First Hospital of China Medical University), Wei Liu(Sichuan University), Wěi Li(Sichuan University), Jianhua Shi(Third Affiliated Hospital of Harbin Medical University)

The Lancet Oncology

November 22, 2017

10.1016/s1470-2045(17)30729-5

Cited by 528

Abstract

Related Papers

No related papers found

Powered by citation graph analysis